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Abstract
Angiopoietins (Ang) have been shown to regulate the process of vasculature and angiogenesis in
tumour. Different angiopoietins have different roles during the angiogenic process. The current
study sought to examine the levels of the expression of Ang-1, Ang-2, Ang-3 and their receptor
Tie-2 in mammary ductal carcinoma and to assess their relevance to prognosis. Fresh frozen ductal
carcinoma tissues (n = 90) and adjacent non-cancerous breast tissues (n = 32) were used. The
expression of Ang-1, Ang-2 and Ang-3 transcripts in cancer and normal breast tissues were
examined quantitatively using quantitative RT-PCR. The protein expression of Ang-1, Ang-2 and
Tie-2 was assessed by immunohistochemistry on frozen sectioned tissues.
Ang-1, Ang-2 and Ang-3 were detected in mammary tissues. Ang-1 was seen in both normal
epithelial cells, breast cancer cells as well as in endothelial cells. Ang-2 was seen at a higher level
than Ang-1 and it is expressed in epithelial, endothelial as well as stromal cells to certain degree.
Ang-1 and Ang-2 transcripts were detected almost equally in cancer and normal breast tissue, and
Ang-3 was high in cancer tissue compared to normal breast but not significant (155 ± 123 & 24.1
± 22.6, P > 0.05). No significant differences were seen between patients with different predicted
prognosis (using the Nottingham Prognostic Index as a guide) (Ang-1 p = 0.34, Ang-2 p = 0.26 and
Ang-3 p = 0.32, respectively). No significant correlation was seen between Ang-1, Ang-2 and Ang-
3 with tumour grade. When the levels of the transcripts were compared against clinical outcome
(disease free, developed recurrence and patients who died of breast cancer), levels of Ang-3
transcript was found to be high in breast cancer patient who had bone metastasis 33.8 ± 28.3,
although the difference was not significant (p = 0.08). No significant difference was seen with levels
of Ang-1 and Ang-2 transcripts and clinical outcomes. Furthermore, no significant trend was
observed between Tie-2 receptor and clinical/pathological parameters in the cohort.
These data suggest that angiopoietins (Ang-1, Ang-2 and Ang-3) are expressed in mammary tissues,
both in normal and tumour. These molecules have limited value in predicting the prognosis and
clinical outcome in patients with mammary ductal carcinoma.
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Background
Angiogenesis, generation of new microvessels from pre-
existing blood vessels, is essential for tumour growth and
invasion [1]. Cancer cells stimulate angiogenesis by secret-
ing angiogenic factors, such as vascular endothelial
growth factor (VEGF), platelet derived growth factor
(PDGF), and fibroblast growth factor (FGF) [2]. Angi-
opoietins, a new family of angiogenic growth factors that
are mostly specific for the vascular endothelium, have
been identified in recent years [3,4]. Ang-1 plays a role in
maintaining and stabilizing mature vessels by promoting
the interaction between endothelial cells and surrounding
support cells, whereas Ang-2 is expressed at sites of vascu-
lar remodelling and is thought to antagonise the stabilis-
ing action of Ang-1 [5,6]. Ang-1 and Ang-2 share about
60% amino acid identity and bind with similar affinity to
the endothelial cell tyrosine kinase receptor Tie2 [4,7].
Angiopoietins and Tie-2 are related to vascular remodel-
ling and sprouting, which occur in a complementary and
coordinated fashion during vascular development, along
with vascular endothelial growth factor (VEGF) and its
tyrosine kinase receptors (Flk-1 and Flt-1) [8].
Breast cancer is the most common form of malignancies
in females in the U.K, and metastasis of breast cancer is
common. About 7% of patients with breast cancer present
with widespread metastases at the initial presentation [9].
The most common sites of metastasis are bone, lungs,
liver, chest wall and central nervous system. Less common
sites are the adrenals, ovaries, pericardium, thyroid and
bone marrow [10]. Tumour cell dissemination is medi-
ated via a number of mechanisms, including local tissue
invasion, haematogenous and/or lymphatic spread as
well as direct seeding of surfaces or body cavities. Angio-
genesis plays a pivotal role in the vascular spread of breast
cancer as well as key to the growth of breast tumours.
Up-regulation of angiopoietins expression has been noted
in many malignant cancers such as gastric carcinoma
[11,12], colorectal cancer [13], hepatocellular carcinoma
[14], renal cell carcinoma [15], ovarian cancer [16] and
non-small lung cancer [17]. Although a few reports on the
expression of angiopoietins in breast cancer have become
available in recent years [18,19], these studies provide lit-
tle conclusive evidence of the correlation between these
molecules and breast cancer progression.
In the present study we examined the expression Ang-1,
Ang-2 and for the first time Ang-3 and their receptor Tie-
2, at mRNA and protein levels in human ductal mammary
carcinomas and investigated the correlation between the
level of the expression of these molecules and clinical/
pathological parameters of breast cancer.
Materials and methods
Tissue collection and preparation
Ductal cancer tissues of the breast (n = 90) were collected
immediately after surgery and stored in a deep freezer
until use. 'Normal' (adjacent non-cancerous) (n = 32),
which were from the same patients with breast cancer and
away from tumour margins were also collected. Patients
were routinely followed clinically after surgery as previ-
ously described [20]. The median followup of the cohort
was 120 months.
Tissue processing, RNA extraction and cDNA synthesis
Total RNA was isolated from frozen-sectioned breast tis-
sues ('normal' (adjacent non-cancerous) and cancer).
Multiple sections were homogenised to extract RNA, using
RNA-Zol reagent (ABgene, Epsom, Surrey, UK), according
to manufacturer's instructions, as we previously reported
[21]. cDNA was generated from 1 μg RNA using an AMV-
reverse transcription kit (ABgene, Epsom, Surrey, UK),
and the standard gunanidine isothiocyanate method as
described in the manufacturer's protocol. The purity and
concentration of RNA was determined by spectrophotom-
etry at 260 nm and 280 nm.
Conventional PCR primers were designed using Beacon
Designer software (Palo Alto, California, USA), to allow
amplification of regions that have no overlap with known
genes and span at least one intron. Primers were synthe-
sized by Life Technologies (Paisley, Scotland, UK) (Table
1).
Quantitative analysis of the Ang-1, Ang-2, Ang-3 and Tie-2 
transcripts in tumour and normal breast Tissues
We employed the iCycler IQ system (BioRad, Camberley,
UK), to quantify the transcript level (shows as copies/μl
calculated from internal standard) of the Ang-1, Ang-2,
Ang-3 and Tie-2, as we previously reported [20]. The sys-
tem used a universal probe (UniPrimer™), which recog-
nised a specific sequence (z sequence), which had been
Table 1: Primer sequence.
Sense primer F1(5'-3') Antisenes primer ZR(5'-3')
Ang-1 ttctcttcccagaaacttca actgaacctgaccgtacacatctccgactt
Ang-2 tcatggaaaacaacactcag Actgaacctgaccgtacattctgtactgcattctgctg
Ang-3 Gtggctgaagaagctagaga Actgaacctgaccgtacagtctgattctgggccatt
Tie-2 Acaacatagggtcaagcaac actgaacctgaccgtacagatggctataaInternational Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
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incorporated into the primers. The reaction was carried
out using IcyclerIQ™ (Bio-Rad) which is equipped with an
optic unit that allows real time detection of 96 reactions,
using the following condition: 94°C for 12 min, 50 cycles
of 94°C for 15 s, 55°C for 40 s and 72°C for 20 s. All sam-
ples were simultaneously examined for Ang-1, Ang-2,
Ang-3 and Tie-2 along with appropriate set of plasmid
standards and negative controls. Primers sequences used
for Ang-1, Ang-2, Ang-3 and Tie-2 were shown in Table 1.
Immunohistochemistry
This was as we recently reported [22]. Briefly, immunohis-
tochemical staining was performed on paired frozen-sec-
tioned tissues (cancer tissue paired with normal
background tissue from the same patient). Frozen sections
were cut, air dried and fixed in 50% methanol and 50%
acetone for 15 minutes. The sections were then air dried
once more for 10 minutes and stored at -20°C in foil-
wrapped slide trays. Immediately before staining speci-
mens were then placed in PBS (Optimax wash buffer) for
5 minutes. The slides were incubated with primary rabbit
polyclonal antibodies against Ang-1, Ang-2 and Tie-2
(Santa Cruz Biotechnologies Inc., Santa Cruz, CA, USA) or
positive control at 1:50 dilution for 1 hour. After 4 washes
with PBS, the slides were placed in universal multi-link
biotinylated (Dako). Secondary antibody at (1:100) dilu-
tion and incubated for 30 minutes. This was followed by
4 washes with PBS. Slides were then placed in avidin
biotin complex (ABC – Vector Labs) for 30 minutes. The
bound antibody complex was detected using diami-
nobenzidine tetrahydrochloride (3,3'-diaminobenzi-
dine)-DAB (Sigma), chromogen for 5 minutes. The slides
were washed with H2O for 5 minutes and placed in
Mayer's haematoxylin for 1 minute, followed by differen-
tiation in H2O for 10 minutes. This was followed by dehy-
dration in methanol (3 times) and clearing in 2 changes
of xylene before mounting under cover slip and examined
on the microscope negative controls (using PBS buffer
instead of the primary antibody) and positive controls
were used in this study. The complete procedure was car-
ried out at room temperature.
Statistical analysis
Statistical analysis was carried out using Minitab version
using a Macro written for the study. Statistical analysis was
performed using a Student's t-test.
Results
The level of the expression Ang-1, Ang-2, Ang-3 and Tie-2 
in tumour and normal background breast tissues and in 
relation to node status
Ang-1, Ang-2, Ang-3 and Tie-2 transcripts were evaluated
using quantitative PCR. The Ang-1 transcript level in back-
ground tissues was marginally higher than in tumour tis-
sues (mean ± SD 141 ± 135 vs 101 ± 100, for background
and tumour respectively, p > 0.05) and Ang-2 (2777 ±
2691 vs 1686 ± 1049 p > 0.05). In contrast, Ang-3 showed
higher level in tumour compared to background tissue
(tumour 155 ± 123 vs background: 24.1 ± 22.6, P > 0.05)
(Figure 1A). Similarly, no significant difference was seen
between node negative and node positive tumours for
Ang-1, Ang-2 and Ang-3 transcript (p > 0.33, p > 0.83 and
p > 0.21 respectively) (Figure 1B).
The level of the Tie-2 receptor showed no significant dif-
ference between tumour and background (tumour: 7.1 ±
4.7 vs background: 7.1 ± 7.4, P = 0.87). Although there
were marginally higher levels of the Tie-2 receptor in node
positive tumours, this did not reach significance (median
value node positive: 11.5 vs median value node negative:
2.9 P = 0.37).
Oestrogen receptor positive breast tissues (ER ve+) had
low level of Ang-2 and Ang-3 compared to ER negative
tumours (ER ve-) (ERve+ for Ang-2: 120 ± 75, Ang-3: 2.4
± 1.6 vs ERve- for Ang-2: 2970 ± 1973 & for Ang-3: 65 ±
85). Ang-1 showed higher levels of transcripts in ERve+
tumours (3.4 ± 3.2), compared with ERve- (2.6 ± 2.3).
Again, the differences were not significant p > 0.05 (Figure
1C).
Correlation of Ang-1, Ang-2, Ang-3 and their receptor Tie-
2 with prognosis and staging
The Nottingham Prognostic Index (NPI) was used as one
parameter to assess the prognosis of the patients, in that
patients with NPI value less than 3.4 (NPI-1) were
regarded as with good prognosis, 3.4–5.4 (NPI-2) moder-
ate prognosis, and NPI>5.4 (NPI-3) with poor prognosis.
The formula for NPI being: NPI = [0.2_size cm] + grade (1
- 3) + nodal status (1 - 3).
There were higher levels of Ang-1, Ang-2 and Ang-3
expression seen in patients with poor prognosis, i.e., NPI-
3 tumours (NPI >5.4), although this did not reach signif-
icance (for Ang-1 NPI-1: 3.69 ± 2.5; NPI-2: 1.8 ± 1.4; NPI-
3: 806 ± 805; P = 0.34) (for Ang-3: NPI-1 0.38 ± 0.28; NPI-
2: 85.7 ± 84.3; NPI-3: 1000 ± 961; P = 0.32). Higher levels
of Ang-2 were observed in moderate prognosis, i.e. NPI
value at 3.4–5.4 (NPI-2) (NPI-1: 1510 ± 1282; NPI-2:
2641 ± 2372; NPI-3: 50.6 ± 23; P = 0.32) (Figure 2A). The
levels of the molecules were also analyzed against TNM
status. No significant difference was seen between any
groups for all three Angs (Figure 2B).
No trend was observable among levels of the angiopoietin
receptor Tie-2 receptor expression and NPI (NPI-1: 11.5 ±
9.4; NPI-2: 2.9 ± 1.1 p > 0.36; NPI-3: 2.9 ± 1.5; P > 0.37)
or with TMN status.International Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
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(A) Levels of expression of Angiopoietins and Tie2 receptor in breast tumour and normal mammary tissues Figure 1
(A) Levels of expression of Angiopoietins and Tie2 receptor in breast tumour and normal mammary tissues. Shown are 
number (mean ± SD) of copies of respective transcripts from 50 ng total RNA. (B) Node negative tumours and node positive 
tumours had different levels of the Angiopoietins and Tie2 receptor transcript. Ang-1 and Ang-3 shown higher levels of copies 
in +ve node in contrast to Tie-2 receptor showed higher transcripts level in -ve node tumour. Both statistically not reached 
significant P > 0.05. (C) Angs/Tie2 and ER status. There was no significant difference in level of expression of all Angs and Tie-
2 breast cancer tissue with/without Estrogens receptor P.0.05.International Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
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Angiopoietin -1, -2, -3 and Tie-2 expressions in different 
tumour grade
The results showed that Ang-1 and Ang-3 expression were
increased with higher grade of tumour, i.e. Grade-3 (173
± 170 & 212 ± 108, respectively) compared with Grade-1
(3.2 ± 2.9 & 1.5 ± 1.3, for Ang-1 and Ang-3 respectively)
(Figure 3). The differences however were not statistically
significant (p > 0.05). The level of Ang-2 transcripts was
higher in Grade-2 tumours compared to Grade -1
(Grade2: 3520 ± 3301 vs Grade 1: 114 ± 69.6). There was
little difference in the level of Tie-2 receptor expression
between the grades of the breast cancers (Grade-1: 2.9 ±
2.1; Grade-2: 4.1 ± 2.3; Grade-3: 9.3 ± 7.5).
Expression of Ang-1, Ang2, Ang-3, Tie-2 and clinical 
outcome following 10-year follow-up
Figure 4 shows data comparing patients with different
clinical outcomes after a median follow-up of 120
months. Patients were divided into those who remained
disease free, those who developed metastasis or local
recurrence, or those who died of breast cancer. Those
patients with metastatic disease had low, but insignificant
levels of Ang-1, Ang-2, Ang-3 and Tie-2 expression com-
pared to patients who remained disease free (metastatic
group: Ang-1: 0.22 ± 0.16, Ang-2: 0.73 ± 1.8, Ang-3: 0.44
± 0.42, Tie-2: 3.3 ± 2.5 vs disease free: Ang-1: 2.75 ± 1.9,
Ang-2: 2314 ± 1525, Ang-3: 50.7 ± 44.5, Tie-2: 8.5 ± 6.5
respectively) (Figure 4A). Moreover, patients with local
recurrence show lower levels of Ang-1,-2,-3 and Tie-2
expression when compared with patients who remained
disease free (Figure 4B). Although patients who died of
breast cancer had higher levels of Ang-1 (886 ± 876) and
Ang-3 (1060 ± 1055) compared to those patients who
were disease free, this was not statistically significant (P =
0.34 & p = 0.37, respectively). In contrast, Ang-2 and Tie-
2 had lower levels of transcripts in patients died from
breast cancer (Figure 4C).
When we combined the three groups (with metastasis,
recurrence, and mortality) to form a poor prognostic
group (referred to as Poor Prog. in Figure 4D) and com-
pared this group with those who remained diseasefree
(Figure 4D), higher levels of all Angiopoietins molecules
were found in the patients with poor prognosis (Ang-1
422 ± 421, Ang-2 416 ± 268, Ang-3 508 ± 502) although
this did not reached a significance.
Immunostaining of mammary epithelial cells and breast 
cancer cells for Ang-1, Ang-2 and their receptor Tie-2
Figure 5 shows the intensity of staining for Ang-1, Ang-2
and their receptor Tie-2 in tumour and background tis-
sues. Stromal cells of normal mammary tissue showed
(A) Quantitative polymerase chain reaction (Q-PCR) analysis of breast cancer tissue samples showing higher transcript levels  of Ang-1 and Ang-3 in poor prognostic index NPI-3 (p > 0.05), and almost similar levels of Ang-1 and Tie2 transcripts in all  three groups Figure 2
(A) Quantitative polymerase chain reaction (Q-PCR) analysis of breast cancer tissue samples showing higher transcript levels 
of Ang-1 and Ang-3 in poor prognostic index NPI-3 (p > 0.05), and almost similar levels of Ang-1 and Tie2 transcripts in all 
three groups. (B) Advanced stage of breast cancer TNM4 showed higher, but insignificant, levels of Ang-1 and Ang-3.International Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
Page 6 of 9
(page number not for citation purposes)
weak staining of Ang-1, Ang-2 and Tie-2 compared with
breast cancer. While the normal breast tissues duct
showed strong staining of Ang-1, Ang-2 and Tie-2 com-
pared with breast cancer duct epithelial cells.
Discussion
Tumour metastasis and rapid growth is critically depend-
ent on blood or lymphatic vessels routes. Prognosis of
solid tumours are closely linked to angiogenic or lym-
phangiogenic factors. Despite numerous studies examin-
ing the angiopoietins in breast tumours, to our best
knowledge the current study is the first study reporting the
relationship of all three angiopoietins and Tie-2 with clin-
ical/pathological of ductal carcinoma of the breast. The
current study has reported that the expression of Angs and
Tie-2 were almost similar in ductal carcinoma and normal
background tissues, with the exception of Ang-3 which
showed higher levels of expression in breast cancer com-
pared with normal breast tissues.
In the current study, we failed to detect a significant differ-
ence when a number of clinical and pathological factors
Angs and Tie2 transcript and tumour grade Figure 3
Angs and Tie2 transcript and tumour grade. Grades 3 breast tumours demonstrate higher levels of Ang-1, Ang-3 and Tie-2 
compared to Grade 1. Ang-2 transcripts level raised in grade 2 breast tumours.International Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
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were considered. Furthermore, all three angiopoietins
showed a marginal higher level of the respective tran-
scripts in advanced breast cancer (NPI3 & Grade-3),
although this did not reach statistical significance. Our
findings are consistent with Currie et al [18] who showed
no significant correlation between Tie2 (or the Angs) with
most clinic/pathological indices in breast cancer.
Although their study demonstrated a significant correla-
tion between oestrogen receptor (ER) status and both Tie2
and Ang-4 expression, our results did not show this corre-
lation which is in agreement with Tautsui et al [19].
It is noteworthy from the present study that low levels of
Angs and their receptor Tie-2 were found in patients who
Q PCR analysis shows association between Angiopoietins and clinical outcome in breast cancer Figure 4
Q PCR analysis shows association between Angiopoietins and clinical outcome in breast cancer. (A&B): Patients who devel-
oped metastatic disease and local recurrence have low levels of Angs and Tie-2 transcripts than who diseases free. (C): Patients 
who died from breast cancer showed higher levels of Ang-1and Ang-3 copies than who diseases free (p > 0.05), whereas Ang-
2 and Tie-2 had higher levels of expression in diseases free compared who died from breast cancer (p > 0.05). (D): Compari-
son between patients who remained disease free and those who developed breast cancer related progression (recurrence, 
metastasis and mortality). Ang-1 and Ang-3 transcripts had higher levels in poor prognosis patients in relation to diseases free 
patients, and again Ang-2 and Tie-2 transcripts had higher levels of expression in diseases free compared to poor prognosis. 
Neither reached a statistical significance.International Seminars in Surgical Oncology 2007, 4:6 http://www.issoonline.com/content/4/1/6
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had cancer metastasis and local recurrence compared to
diseases free after 10 years fellow up. Patients who died
from breast cancer had higher levels of only Ang-1 and
Ang-3. These findings are in contrast with Sfiligoi et al.
[23] who reported that Ang-2 associates with tumour
aggressiveness, whereas Ang-1 does not. Moreover, previ-
ous studies have demonstrated that the expression of Angs
has a strong prognostic significance in breast cancer and
correlates with MVD and VEGF expression [19,23], while
Currie et al. [18] found no significant relation between
Ang-2 expression and MVD in breast cancer. One of the
reasons for these discrepancies may be the difference in
methodologies and the sample size used in the respective
studies. The current study was limited by its sample
number. A study with bigger cohort will certainly help to
further clarify the observations.
Despite some studies show a significant correlation
between Angs expression and clinic/pathological parame-
ters in cancers other than breast cancer including gastric,
liver and colorectal cancer [11,12,14]. It is clear from the
present study and indeed other limited reports [18] that
the case in ductal carcinoma of the breast is far from being
clear. A number of possibilities exist. Firstly, different
organs may have a difference vasculature network. In ear-
lier studies examining the mechanism of human breast
cancer angiogenesis, it has been demonstrated that
endothelial cell proliferation is a relatively rare event in
breast cancer [24, 25]. Secondly, breast cancer is a hetero-
geneous disease whose clinical outcome encompasses a
wide spectrum of possibilities from definitive cure to early
death. Axillary nodal status has been shown to be one of
the most important prognostic factors in the patients,
with up to 30% of node-negative patients eventually
relapse.
Taken together, although angiopoietins have been shown
to be expressed at higher levels in GI tumours, the same
has not been seen in breast cancer as reported here. It is
possible therefore that angiopoietins and Tie2 play a
lesser role in the progression of breast, compared with
other angiogenic factors and indeed lymphangiogenic fac-
tors as widely reported. In summary, although our study
shows high levels of Angs mRNA in advanced breast
tumour such as in Grade-3 and NPI3 compared with early
stage of cancer (Grade-1&NPI1), no significant difference
is obtained. We conclude therefore that these molecules
may not be significant prognostic factors in ductal carci-
noma of the breast. The observation warrant further stud-
ies in larger cohorts.
Immunostaining of normal background breast tissue (left Panel) and breast cancer tissue (Right Panel) for Ang-1, Ang-2 and  Tie-2 (original magnification, 40×, 100×; 200× and 400×) Figure 5
Immunostaining of normal background breast tissue (left Panel) and breast cancer tissue (Right Panel) for Ang-1, Ang-2 and 
Tie-2 (original magnification, 40×, 100×; 200× and 400×). A higher intensity of staining was noted in epithelial cells of breast 
cancer compared with non-cancerous mammary tissue. Strong staining of Ang-1, Ang-2 and Tie-2 is shown in normal breast 
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